IL29 (Interferon Lambda 1, also known as IFN-λ1) is a cytokine gene encoding a Type III interferon that plays crucial roles in antiviral immunity, immune modulation, and neuroinflammation. Although primarily studied in the context of viral infections and autoimmune diseases, emerging evidence positions IL29 as a significant player in neurodegenerative disease pathogenesis through its effects on microglia, astrocytes, and neuroinflammatory cascades. [@kotenko2002][@cully2019]
The IL29 gene is located on chromosome 19q13.2 within the Type III interferon gene cluster, which includes IL28A (IFN-λ2) and IL28B (IFN-λ3). The gene spans approximately 3.5 kb and consists of 5 exons encoding a 200-amino acid secreted protein. IL29 shares the same receptor complex (IFN-λR1/IL-10Rβ) with other Type III interferons but signals through a distinct pathway compared to Type I interferons (IFN-α/β). [@lazear2019]
The IL-29 protein possesses:
IL29 expression is induced by viral infection, toll-like receptor activation, and pro-inflammatory cytokines. Unlike Type I interferons, which are expressed ubiquitously, IFN-λ signaling is largely restricted to epithelial cells and certain immune cells.
IL29 signals through a heterodimeric receptor complex:
IL29 exhibits complex and context-dependent roles in Alzheimer's disease pathogenesis:
Microglial Activation: IL-29 promotes M1 pro-inflammatory microglial polarization, increasing expression of TNF-α, IL-1β, and IL-6 in the brain. This polarization contributes to chronic neuroinflammation and drives disease progression. [@xu2019]
Amyloid Pathology: Studies demonstrate that IL-29 enhances amyloid-β production by upregulating β-secretase (BACE1) expression in neurons and glia. IFN-λ signaling in microglia promotes phagocytic activity but may also increase inflammatory cytokine release that damages neurons.
Tau Pathology: IL-29-mediated neuroinflammation accelerates tau hyperphosphorylation through GSK-3β activation. The inflammatory milieu created by chronic IFN-λ exposure promotes tau seeding and propagation.
Neuronal Dysfunction: IFN-λ signaling in neurons induces expression of antiviral genes that may inadvertently target neuronal survival pathways. Chronic exposure leads to synaptic dysfunction and dendritic spine loss. [@zhao2021]
Dopaminergic Neuron Vulnerability: IL-29 expression is elevated in the substantia nigra of PD patients. This cytokine promotes neuroinflammation that specifically targets dopaminergic neurons in the substantia nigra pars compacta.
α-Synuclein Pathology: IFN-λ signaling enhances α-synuclein aggregation and propagation. Microglial activation by IL-29 creates a permissive environment for Lewy body formation. [@kim2021]
Neuroinflammation: IL-29 amplifies the innate immune response in PD, increasing pro-inflammatory cytokine production and microglial phagocytic activity. However, this comes at the cost of chronic neuroinflammation.
Therapeutic Potential: Interestingly, some studies show that IFN-λ treatment can reduce α-synuclein pathology in experimental models, suggesting a potential biphasic effect depending on timing and context. [@tateishi2020]
Motor Neuron Vulnerability: IL-29 is upregulated in ALS patients and SOD1 transgenic mice. The cytokine promotes inflammatory activation of microglia that attack motor neurons.
Disease Progression: Treatment with IFN-λ exacerbates disease in ALS mouse models, accelerating motor neuron loss and reducing survival. Neutralization of IFN-λ improves outcomes. [@li2019]
Astrocyte Dysfunction: IL-29 modulates astrocyte reactivity in ALS, promoting pro-inflammatory astrocyte phenotypes that fail to support motor neuron survival.
Demyelination: IFN-λ is upregulated in MS lesions and promotes oligodendrocyte death. The cytokine inhibits oligodendrocyte precursor cell (OPC) differentiation, impairing remyelination.
Blood-Brain Barrier: IL-29 increases expression of matrix metalloproteinases (MMPs) that degrade the blood-brain barrier, facilitating immune cell infiltration.
Clinical Trials: Recombinant IFN-λ is being explored therapeutically in MS, with Phase 2 trials showing some benefit in reducing relapse rates.